SCHEMBL3537473

SCHEMBL3537473

c1cc2c(ccc3ncoc32)o1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 3/20 0.42
MAOB P27338 3/20 0.42
NFKB1 P19838 1/20 0.42
CYP1A1 P04798 3/20 0.34
CYP1B1 Q16678 3/20 0.34
CYP1A2 P05177 1/20 0.34
HTR2C P28335 2/20 0.33
HTR2A P28223 1/20 0.33
HTR2B P41595 1/20 0.33
DYRK1A Q13627 3/20 0.32
PAX8 Q06710 1/20 0.32
FTO Q9C0B1 1/20 0.31
ALDH1A1 P00352 2/20 0.31
MEN1 O00255 1/20 0.31
GAA P10253 1/20 0.31
KMT2A Q03164 1/20 0.31
CCNT1 O60563 1/20 0.31
CDK7 P50613 1/20 0.31
CDK9 P50750 1/20 0.31
CCNH P51946 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29873503 0.75 DYRK1A (0.36) DYRK1AALDH1A1MEN1GAAKMT2A
SCHEMBL28449487 0.73 MAOA (0.35) MAOAMAOBNFKB1HTR2CDYRK1A
SCHEMBL6125854 0.71 DYRK1A (0.37) HTR2CHTR2ADYRK1AALDH1A1MEN1
SCHEMBL30662543 0.71 MAOA (0.36) MAOAMAOBNFKB1HTR2CHTR2A
SCHEMBL4429415 0.69 PAX8 (0.48) MAOAMAOBNFKB1CYP1A1CYP1B1
SCHEMBL7096111 0.69 MAOA (0.34) MAOAMAOBHTR2CHTR2AHTR2B
SCHEMBL2245348 0.68 HTR2C (0.37) MAOAMAOBNFKB1HTR2CHTR2A
SCHEMBL3938313 0.68 MAPT (0.58) CYP1A1CYP1B1CYP1A2ALDH1A1MEN1
SCHEMBL29728143 0.68 CYP3A4 (0.52) CYP1A1CYP1B1CYP1A2PAX8ALDH1A1
SCHEMBL3910922 0.68 CYP3A4 (0.52) CYP1A1CYP1B1CYP1A2PAX8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8071620-B2 Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2011-12-06 US disclosed
US-20100093743-A1 CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS TOPOTARGET UK LIMITED (GB) 2010-04-15 US disclosed
US-7652036-B2 Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2010-01-26 US disclosed
US-20060079528-A1 (E)-3-(1,3-Benzoxazol-2-yl)-N-hydroxy-2-propenamide; Methyl (E)-3-(2-quinolinyl)-2-propenoate; histone deacetylase inhibitors; inflammatory disease; cancer TOPOTARGET UK LIMITED (GB) 2006-04-13 US disclosed
EP-1599449-A2 CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS TopoTarget UK Limited (GB) 2005-11-30 EP disclosed
WO-2004076386-A2 CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS TOPOTARGET UK LIMITED (GB) 2004-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079528-A1 (E)-3-(1,3-Benzoxazol-2-yl)-N-hydroxy-2-propenamide; Methyl (E)-3-(2-quinolinyl)-2-propenoate; histone deacetylase inhibitors; inflammatory disease; cancer HDAC1, HDAC11, HDAC5 MAOA 3243/4885MAOB 3608/4885NFKB1 177/4885
US-20100093743-A1 CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS HDAC1, HDAC7, HDAC5 MAOA 2551/4885MAOB 3206/4885NFKB1 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.